Literature DB >> 19863866

Hypertension and diastolic heart failure.

Alan H Gradman1, J Travis Wilson.   

Abstract

In patients with hypertension, pressure overload leads to left ventricular hypertrophy (LVH), myocardial fibrosis, and impaired diastolic filling without systolic dysfunction. Presently, diastolic heart failure accounts for about 50% of the heart failure population. Fatigue, dyspnea, reduced exercise tolerance, and peripheral edema are common presenting complaints. As a group, patients with diastolic heart failure are older and predominantly female. Diuretics are effective for treating congestive symptoms. beta Blockers and heart rate-lowering calcium blockers show benefit in smaller studies but have not been evaluated in definitive clinical trials. Renin-angiotensin-aldosterone system blockers reduce blood pressure, LVH, and myocardial fibrosis; however, long-term studies with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers demonstrate little effect on symptoms or survival, and inconsistent effects on heart failure hospitalization. At present, evidence-based treatment includes antihypertensive therapy to reduce progression from hypertension to heart failure. In patients with established heart failure, diuretics and other empiric treatments are used to control symptoms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19863866     DOI: 10.1007/s11886-009-0061-5

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  41 in total

Review 1.  NO and cardiac diastolic function.

Authors:  W J Paulus; A M Shah
Journal:  Cardiovasc Res       Date:  1999-08-15       Impact factor: 10.787

Review 2.  Coronary artery disease in patients with heart failure and preserved systolic function.

Authors:  Lubna Choudhury; Mihai Gheorghiade; Robert O Bonow
Journal:  Am J Cardiol       Date:  2002-03-15       Impact factor: 2.778

Review 3.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.

Authors:  Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder
Journal:  Am J Med       Date:  2003-07       Impact factor: 4.965

Review 4.  From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.

Authors:  Alan H Gradman; Fadi Alfayoumi
Journal:  Prog Cardiovasc Dis       Date:  2006 Mar-Apr       Impact factor: 8.194

5.  2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.

Authors:  Mariell Jessup; William T Abraham; Donald E Casey; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Marvin A Konstam; Donna M Mancini; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  Circulation       Date:  2009-03-26       Impact factor: 29.690

6.  Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Authors:  C G Brilla; R C Funck; H Rupp
Journal:  Circulation       Date:  2000-09-19       Impact factor: 29.690

7.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.

Authors:  J F Setaro; B L Zaret; D S Schulman; H R Black; R Soufer
Journal:  Am J Cardiol       Date:  1990-10-15       Impact factor: 2.778

8.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

9.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

Authors:  Marcus D Flather; Marcelo C Shibata; Andrew J S Coats; Dirk J Van Veldhuisen; Aleksandr Parkhomenko; Joszef Borbola; Alain Cohen-Solal; Dan Dumitrascu; Roberto Ferrari; Philippe Lechat; Jordi Soler-Soler; Luigi Tavazzi; Lenka Spinarova; Jiri Toman; Michael Böhm; Stefan D Anker; Simon G Thompson; Philip A Poole-Wilson
Journal:  Eur Heart J       Date:  2005-01-09       Impact factor: 29.983

10.  Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure.

Authors:  Philip M Mottram; Brian Haluska; Rodel Leano; Diane Cowley; Michael Stowasser; Thomas H Marwick
Journal:  Circulation       Date:  2004-07-26       Impact factor: 29.690

View more
  14 in total

1.  Effects of interleukin-33 on cardiac fibroblast gene expression and activity.

Authors:  Jinyu Zhu; Wayne Carver
Journal:  Cytokine       Date:  2012-03-23       Impact factor: 3.861

2.  Two dimensional and real-time three dimensional ultrasound measurements of left ventricular diastolic function after marathon running: results from a substudy of the BeMaGIC trial.

Authors:  Astrid Roeh; Tibor Schuster; Philip Jung; Jens Schneider; Martin Halle; Johannes Scherr
Journal:  Int J Cardiovasc Imaging       Date:  2019-06-01       Impact factor: 2.357

3.  Elevated Plasma Factor VIII in Patients with Ischemic Stroke: Does it have any Association with Hypertensive Heart Disease?

Authors:  Joseph Tarsia; Tiffany R Chang; Aimee Aysenne; Amelia K Boehme; Alton E Sartor; Karen C Albright; Ethan Arda Yalvac; Rebecca Kruse-Jarres; Cindy Leissinger; Sheryl Martin-Schild
Journal:  J Neurol Disord Stroke       Date:  2013-09-13

4.  Mast Cell Inhibition Attenuates Cardiac Remodeling and Diastolic Dysfunction in Middle-aged, Ovariectomized Fischer 344 × Brown Norway Rats.

Authors:  Hao Wang; Jaqueline da Silva; Allan Alencar; Gisele Zapata-Sudo; Marina R Lin; Xuming Sun; Sarfaraz Ahmad; Carlos M Ferrario; Leanne Groban
Journal:  J Cardiovasc Pharmacol       Date:  2016-07       Impact factor: 3.105

Review 5.  Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy.

Authors:  Mark T Waddingham; Amanda J Edgley; Hirotsugu Tsuchimochi; Darren J Kelly; Mikiyasu Shirai; James T Pearson
Journal:  World J Diabetes       Date:  2015-07-10

6.  Reversal of maladaptive fibrosis and compromised ventricular function in the pressure overloaded heart by a caveolin-1 surrogate peptide.

Authors:  Dorea Pleasant-Jenkins; Charles Reese; Panneerselvem Chinnakkannu; Harinath Kasiganesan; Elena Tourkina; Stanley Hoffman; Dhandapani Kuppuswamy
Journal:  Lab Invest       Date:  2017-01-23       Impact factor: 5.662

Review 7.  Cardiac Remodeling, Adaptations and Associated Myocardial Mechanics in Hypertensive Heart Diseases.

Authors:  Yau-Huei Lai; Chi-In Lo; Yih-Jer Wu; Chung-Lieh Hung; Hung-I Yeh
Journal:  Acta Cardiol Sin       Date:  2013-01       Impact factor: 2.672

8.  Contractile protein phosphorylation predicts human heart disease phenotypes.

Authors:  Lori A Walker; David A Fullerton; Peter M Buttrick
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-05       Impact factor: 4.733

Review 9.  Heart failure with preserved ejection fraction.

Authors:  James D Gladden; Wolfgang A Linke; Margaret M Redfield
Journal:  Pflugers Arch       Date:  2014-03-25       Impact factor: 3.657

10.  Left ventricular diastolic dysfunction and plasma asymmetric dimethylarginine concentration in persons with essential hypertension.

Authors:  Rafał Poręba; Paweł Gać; Małgorzata Poręba; Arkadiusz Derkacz; Angelika Chachaj; Grzegorz Mazur; Andrzej Szuba
Journal:  Arch Med Sci       Date:  2015-06-19       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.